MERIDIAN, Idaho, Nov. 20 /PRNewswire-FirstCall/ -- RxElite Holdings, Inc., (OTC Bulletin Board: RXEI) a developer, manufacturer, and marketer of specialty generic prescription drug products will hold a conference call to review its financial results for the third quarter ended September 30, 2007, on Tuesday, November 27, 2007, at 2:00 p.m. EST.
The dial-in numbers are: 1-800-567-5900 (Toll Free in USA and Canada) and 1-702-835-5025 (for callers outside USA and Canada).
Participant Access Code: 640989
Callers will be muted upon joining the conference. Press 7 on your telephone to un-mute and ask questions. The call will also be available for subsequent replay on the company's website. To listen via this alternative, go to the Investor Relations page at http://www.rxelite.com.
About RxElite, Inc.
RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 involving
known and unknown risks, delays, and uncertainties that may cause our
actual results or performance to differ materially from those expressed or
implied by these forward-looking statements. These risks, delays, and
uncertainties include, but are not limited to: risks associated with the
uncertainty of future financial results, our reliance on our sole supplier,
the limited diversification of our product offerings, additional financing
requirements, development of new products, government approval processes,
the impact of competitive products or pricing, technological changes, the
effect of economic conditions and ot
|SOURCE RxElite Holdings, Inc.|
Copyright©2007 PR Newswire.
All rights reserved